Beta-thalassemia secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Beta-thalassemia}} | {{Beta-thalassemia}} | ||
<ref name="pmid31030806">{{cite journal |vauthors=Khandros E, Kwiatkowski JL |title=Beta Thalassemia: Monitoring and New Treatment Approaches |journal=Hematol Oncol Clin North Am |volume=33 |issue=3 |pages=339–353 |date=June 2019 |pmid=31030806 |doi=10.1016/j.hoc.2019.01.003 |url=}}</ref><ref name="pmid34738740">{{cite journal |vauthors=Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi SAR, Sadia, Irfan M, Khan MA |title=Current status of beta-thalassemia and its treatment strategies |journal=Mol Genet Genomic Med |volume=9 |issue=12 |pages=e1788 |date=December 2021 |pmid=34738740 |pmc=8683628 |doi=10.1002/mgg3.1788 |url=}}</ref>. | |||
==References== | ==References== | ||
Revision as of 22:03, 21 August 2023
|
Beta-thalassemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Beta-thalassemia secondary prevention On the Web |
|
American Roentgen Ray Society Images of Beta-thalassemia secondary prevention |
|
Risk calculators and risk factors for Beta-thalassemia secondary prevention |
References
- ↑ Khandros E, Kwiatkowski JL (June 2019). "Beta Thalassemia: Monitoring and New Treatment Approaches". Hematol Oncol Clin North Am. 33 (3): 339–353. doi:10.1016/j.hoc.2019.01.003. PMID 31030806.
- ↑ Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi S, Sadia, Irfan M, Khan MA (December 2021). "Current status of beta-thalassemia and its treatment strategies". Mol Genet Genomic Med. 9 (12): e1788. doi:10.1002/mgg3.1788. PMC 8683628 Check
|pmc=value (help). PMID 34738740 Check|pmid=value (help). Vancouver style error: initials (help)